A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Conditions: Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)
Interventions: Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily; Drug: Obicetrapib 10 mg; Other: Placebo
Sponsors: NewAmsterdam Pharma
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.